HempFusion(R) Participates and Sponsors Industry Leading Study on CBD and Human Health
June 25th, 2020
News, Top News
DENVER, COLORADO, June 25, 2020 – HempFusion® (“the Company”), a leading dietary supplements company focused on products that contain Hemp/CBD in the United States with distribution of its family of brands to approximately 4,000 retailers across 47 states, is pleased to announce the sponsorship and participation in ValidCare’s scientific study that addresses the Food and Drug Administration’s (“FDA”) previous questions about CBD products. ValidCare will be conducting a human trial and study to determine if daily use of full-spectrum hemp-derived CBD or CBD isolate has any impact on the human liver. HempFusion is one of ten select CBD companies sponsoring and participating in ValidCare’s ground breaking study.
“We are excited that HempFusion is one of the select companies participating in this study as they have demonstrated leadership in regulatory compliance and concern for consumer safety,” stated Patrick McCarthy, CEO of ValidCare. “What makes this study unique is we are capturing real world evidence from real consumers, specifically on how they use CBD products and how their bodies react to those products, particularly with respect to liver safety. We believe this real world evidence is important to the FDA and could be used to guide policy moving forward,” continued McCarthy.
ValidCare expects the study to begin in the third quarter of 2020 and targets completion by the end of the year. The third-party scientific data generated from the companies participating in this study is intended to address some of the FDA’s specific requests about CBD products.
“We are incredibly proud to participate in ValidCare’s study and help advance scientific research surrounding CBD”, stated Jason Mitchell, N.D., Co-CEO of HempFusion. “As a Company, we are built on a foundation of regulatory compliance as well as consumer safety and participation in this study helps establish HempFusion as a leader in the global CBD industry”, continued Mitchell.
HempFusion is a premium wellness company featuring dietary supplements including hemp-based cannabidiol (“CBD”) with distribution of its family of brands to approximately 4,000 retailers across 47 US states. The Company strives to maintain the highest level of compliance in the industry. HempFusion’s wide variety of 25+ CBD products with a full spectrum of cannabinoids and other constituents are sourced from quality phytocompounds manufactured under cGMP standards designed to attain efficacy and safety. HempFusion’s primary focus is formulating and marketing premium consumer-specific product lines with various delivery methods, across multiple distribution platforms. The Company’s CBD products are based on a proprietary Whole Food Panoramic Full-Spectrum Hemp Complex™ and are available through independently owned and national chain health food stores, or by visiting www.hempfusion.com.
Validcare provides clinical research outsourcing (CRO) and consumer intelligence solutions for the consumer packaged goods (CPG) and life sciences industries. Validcare’s proprietary platform supports virtual research powered by real world evidence (RWE). This includes self reported consumer data to deliver insights that help improve research, regulations, product development and consumer health. For more information, visit http://www.validcare.com or call 844-825-4322.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.